ATRI:NSD-Atrion Corporation (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 709.49

Change

-19.49 (-2.67)%

Market Cap

USD 1.28B

Volume

7.18K

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Germany, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, mixes critical drugs, controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measure the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas. Address: One Allentown Parkway, Allen, TX, United States, 75002-4211

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-20 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical Inc

-23.28 (-2.24%)

USD123.43B 77.45 62.08
HOLX Hologic Inc

-0.90 (-1.16%)

USD19.68B 9.95 7.22
RGEN Repligen Corporation

-0.85 (-0.28%)

USD16.87B 170.59 106.78
MASI Masimo Corporation

-1.34 (-0.49%)

USD15.11B 71.08 50.02
NVCR NovoCure Limited

-3.83 (-2.92%)

USD13.58B 1,480.87 528.28
XRAY DENTSPLY SIRONA Inc

-1.58 (-2.58%)

USD13.38B 36.53 17.47
STAA STAAR Surgical Company

-3.31 (-2.31%)

USD6.80B 351.40 218.19
ICUI ICU Medical Inc

-1.59 (-0.66%)

USD5.10B 50.50 21.60
MMSI Merit Medical Systems Inc

-0.08 (-0.11%)

USD4.03B 143.30 31.03
ATRC AtriCure Inc

-4.12 (-5.37%)

USD3.33B N/A N/A

ETFs Containing ATRI

Symbol Name Weight Mer Price(Change) Market Cap
RNSC First Trust Small Cap US .. 0.00 % 0.60 %

-0.54 (-1.91%)

USD0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.47% 50% F 59% F
Dividend Return 0.85% 75% C 25% F
Total Return 11.32% 53% F 59% F
Trailing 12 Months  
Capital Gain 11.40% 30% F 36% F
Dividend Return 1.13% 50% F 20% F
Total Return 12.53% 30% F 36% F
Trailing 5 Years  
Capital Gain 67.94% 31% F 62% D-
Dividend Return 6.75% 50% F 20% F
Total Return 74.68% 31% F 62% D-
Average Annual (5 Year Horizon)  
Capital Gain 7.75% 20% F 47% F
Dividend Return 0.87% 50% F 23% F
Total Return 8.61% 20% F 45% F
Risk Return Profile  
Volatility (Standard Deviation) 22.55% 97% A+ 73% C
Risk Adjusted Return 38.21% 37% F 54% F
Market Capitalization 1.28B 58% F 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 41.58 57% F 24% F
Price/Book Ratio 5.45 42% F 27% F
Price / Cash Flow Ratio 32.57 36% F 13% F
EV/EBITDA 28.16 50% F 27% F
Management Effectiveness  
Return on Equity 13.19% 79% C+ 77% C+
Return on Invested Capital 12.26% 82% B- 82% B-
Return on Assets 7.73% 75% C 89% B+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 11.45 6% F 9% F
Short Percent 5.31% 27% F 33% F
Beta 0.08 94% A 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector